3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
8
Neoplasm Metastasis
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Endometrial Neoplasms
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-Positive Primary Breast Cancer
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Interventions
durvalumab
2
Gemcitabine
2
Cisplatin
2
trastuzumab deruxtecan
1
tivozanib
1
guadecitabine
1
fludarabine
1
atezolizumab
1
Taxes
1
Specimen Handling
1
Platinum
1
Oxaliplatin
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled